Pharmaceuticals

Latest California Healthline Stories

Colorado Becomes the First State to Ban So-Called Abortion Pill Reversals

The controversial practice of administering progesterone to people after they have taken the abortion pill mifepristone may be coming to an end in Colorado. Pills have emerged as the latest front in the war over abortion since the U.S. Supreme Court overturned Roe v. Wade last summer.

Listen: Mifepristone Remains Available for Now. What Happens Next?

The Supreme Court on April 21 ruled that the abortion pill mifepristone should remain widely available while the lower courts consider the issue, blocking earlier rulings that banned or restricted access to the drug. KFF Health News’ Julie Rovner joined NPR’s “Weekend All Things Considered” to discuss the complicated case.

The Biden Administration Vowed to Be a Leading Voice on Opioid Settlements But Has Gone Quiet

Billions of dollars are headed to state and local governments to address the opioid crisis. Policy experts and advocates expect the federal government to play a role in overseeing the use of the money. Failure to do so, they say, could lead to wasted opportunities. And, since Medicaid helps pay health care costs, the feds could have a claim to portions of states’ opioid settlements.

KFF Health News' 'What the Health?': Will They or Won’t They (Block the Abortion Pill)?

The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Mary Agnes Carey to discuss these issues and more.

Redes sociales alimentan obsesión por las drogas para bajar de peso, sin hablar de riesgos

La competencia para hacerse con un mercado que podría valer $100.000 millones al año, solo para los fabricantes de medicamentos, ha desencadenado una ola de publicidad que preocupa a las autoridades sanitarias  y médicos de todo el mundo.